Senti Biosciences, Inc. is a biotechnology company. The company is headquartered in South San Francisco, California and currently employs 122 full-time employees. The company went IPO on 2021-05-26. The firm is developing cell and gene therapies engineered with its gene circuit platform technologies to fight challenging diseases. The firm's products include SENTI-202, SENTI-401 and SENTI-301A. The company is developing its SENTI-202 product candidate as a Logic Gated (OR + NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow. SENTI-401 for the potential treatment of colorectal cancer (CRC) and Other Solid Tumors. SENTI-301A for the potential treatment of HCC and Other Solid Tumors. Its gene circuit platform technologies are designed to be applied in a modality-agnostic manner, with applicability to natural killer (NK) cells, T cells, tumor infiltrating lymphocytes (TILs), stem cells, including induced Pluripotent Stem Cells (iPSCs) Hematopoietic Stem Cells (HSCs), in vivo gene therapy, such as adeno associated virus, and messenger ribonucleic acid.